Last reviewed · How we verify

Omacor + simvastatin — Competitive Intelligence Brief

Omacor + simvastatin (Omacor + simvastatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Omega-3 fatty acid + HMG-CoA reductase inhibitor (statin). Area: Cardiovascular.

marketed Omega-3 fatty acid + HMG-CoA reductase inhibitor (statin) VLDL production pathway (Omacor); HMG-CoA reductase (simvastatin) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Omacor + simvastatin (Omacor + simvastatin) — Provident Clinical Research. Omacor (omega-3 fatty acids) reduces triglycerides and supports cardiovascular health, while simvastatin lowers LDL cholesterol by inhibiting HMG-CoA reductase.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Omacor + simvastatin TARGET Omacor + simvastatin Provident Clinical Research marketed Omega-3 fatty acid + HMG-CoA reductase inhibitor (statin) VLDL production pathway (Omacor); HMG-CoA reductase (simvastatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Omega-3 fatty acid + HMG-CoA reductase inhibitor (statin) class)

  1. Provident Clinical Research · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Omacor + simvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/omacor-simvastatin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: